SynthesisBMC nephrology2026
Cytomegalovirus and BK polyomavirus in belatacept-treated kidney transplant recipients: a systematic review and meta-analysis.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis evaluated the risk of cytomegalovirus (CMV) and BK virus infections in kidney transplant recipients receiving belatacept-based immunosuppression compared to calcineurin inhibitor (CNI)-based regimens. Seven studies (six randomized controlled trials and one cohort study) involving 1,625 patients were analyzed. Pooled results showed little to no evidence of a difference in CMV infection risk between belatacept and CNI-treated patients (odds ratio [OR] 1.24, 95% confidence interval [CI] 0.80-1.94; P = 0.34). However, there was little to no evidence of a difference in BK virus infection risk, though the point estimate suggested a possible increase (OR 2.11, 95% CI 0.71-6.33, P = 0.18). Heterogeneity was low across studies (I² = 0%). A sensitivity analysis excluding the single non-randomized cohort study (i.e., restricted to the randomized controlled trials) showed little to no evidence of a difference in CMV infection risk (OR 1.16, 95% CI 0.57-2.37; P = 0.69). While belatacept offers renal and metabolic advantages over CNIs, the potential for CMV and BK viremia necessitates careful monitoring, particularly in high-risk patients. Standardized viral surveillance and further research in larger cohorts are needed to clarify long-term infection risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.